A Cell Line for Detection of Botulinum Neurotoxin Type B

Botulinum neurotoxins (BoNTs) type A and type B are commonly used as biopharmaceutics for neurological diseases, uniquely allowing months-long paralysis of target muscles. Their exquisite neuronal specificity is conferred by a multistep process of binding, internalization, cytosolic escape and cleavage of the neuron-specific proteins, SNAP-25 and vesicle-associated membrane proteins (VAMPs), ultimately to inhibit secretion of neurotransmitters. Currently the mouse lethality bioassay is the only available method for quality control testing of VAMP-cleaving botulinum products. Refined assays for botulinum product testing are urgently needed. Specifically, in vitro replacement assays which can account for all steps of BoNT intoxication are in high demand. Here, we describe a novel SiMa cell-based approach where re-engineering of the VAMP molecule allows detection of all BoNT/B intoxication steps using a luminescent enzymatic reaction with sensitivity comparable to mouse LD50 bioassay. The presented one-step enzyme-linked immunosorbent assay meets 3Rs (replacement, reduction, and refinement of the use of animals) objectives, is user-friendly and will accelerate development of new botulinum drugs. The sensitive enzymatic reporter cell line could also be adapted for the detection of toxin activity during the manufacture of botulinum and tetanus vaccines.

[1]  D. Sesardic,et al.  SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E , 2017, Toxins.

[2]  F. Bard,et al.  VAMP3/Syb and YKT6 are required for the fusion of constitutive secretory carriers with the plasma membrane , 2017, PLoS genetics.

[3]  J. Trösemeier,et al.  In vitro potency determination of botulinum neurotoxin B based on its receptor-binding and proteolytic characteristics. , 2016, Toxicology in vitro : an international journal published in association with BIBRA.

[4]  B. Davletov,et al.  Botulinum neurotoxin type C protease induces apoptosis in differentiated human neuroblastoma cells , 2016, Oncotarget.

[5]  M. Tesar,et al.  NanoLuc Luciferase – A Multifunctional Tool for High Throughput Antibody Screening , 2016, Front. Pharmacol..

[6]  B. Davletov,et al.  Botulinum protease-cleaved SNARE fragments induce cytotoxicity in neuroblastoma cells , 2014, Journal of neurochemistry.

[7]  C. Montecucco,et al.  Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain , 2013, FEBS letters.

[8]  K. Aoki,et al.  Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay , 2012, PloS one.

[9]  T. Binz,et al.  Human synaptotagmin‐II is not a high affinity receptor for botulinum neurotoxin B and G: Increased therapeutic dosage and immunogenicity , 2012, FEBS letters.

[10]  Eric A. Johnson,et al.  Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  R. Yu,et al.  Structures, biosynthesis, and functions of gangliosides--an overview. , 2011, Journal of oleo science.

[12]  Andreas Luch,et al.  The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin Potency Testing , 2010, Alternatives to laboratory animals : ATLA.

[13]  T. Binz,et al.  Clostridial Neurotoxins: Mechanism of SNARE Cleavage and Outlook on Potential Substrate Specificity Reengineering , 2010, Toxins.

[14]  T. Binz,et al.  Cell entry strategy of clostridial neurotoxins , 2009, Journal of neurochemistry.

[15]  H. Bigalke,et al.  Botulinum neurotoxin — from laboratory to bedside , 2006, Neurotoxicity Research.

[16]  M. Caleo,et al.  Long-Distance Retrograde Effects of Botulinum Neurotoxin A , 2008, The Journal of Neuroscience.

[17]  C. Montecucco,et al.  Presynaptic neurotoxins with enzymatic activities. , 2008, Handbook of experimental pharmacology.

[18]  M. Wendl.  This is an Open Access article distribut... , 2007 .

[19]  J. Chaddock,et al.  Clostridial neurotoxins: structure-function led design of new therapeutics , 2006, Cellular and Molecular Life Sciences.

[20]  B. Davletov,et al.  Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins , 2005, Trends in Neurosciences.

[21]  C. Montecucco,et al.  Botulinal neurotoxins: revival of an old killer. , 2005, Current opinion in pharmacology.

[22]  C. Montecucco,et al.  Comparison of the pH-induced conformational change of different clostridial neurotoxins. , 2004, Biochemical and biophysical research communications.

[23]  H. Bigalke,et al.  The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction , 2003, Molecular microbiology.

[24]  P. Edmonds,et al.  Comparison of the mouse bioassay and enzyme-linked immunosorbent assay procedures for the detection of type A botulinal toxin in food. , 2004, Journal of food protection.

[25]  D. Sesardic,et al.  Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. , 2003, Biologicals : journal of the International Association of Biological Standardization.

[26]  M. Delgado.  Botulinum neurotoxin type A. , 2003, The Journal of the American Academy of Orthopaedic Surgeons.

[27]  B. Davletov,et al.  Getting muscles moving again after botulinum toxin: novel therapeutic challenges. , 2003, Trends in molecular medicine.

[28]  Leonard A. Smith,et al.  Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A , 2003, The Journal of Biological Chemistry.

[29]  M. Montal,et al.  Translocation of botulinum neurotoxin light chain protease through the heavy chain channel , 2003, Nature Structural Biology.

[30]  C. Schengrund,et al.  Botulinum Neurotoxin A Activity Is Dependent upon the Presence of Specific Gangliosides in Neuroblastoma Cells Expressing Synaptotagmin I* , 2002, The Journal of Biological Chemistry.

[31]  G. Nolan,et al.  Rapid Production of Retroviruses for Efficient Gene Delivery to Mammalian Cells Using 293T Cell–Based Systems , 1999, Current protocols in immunology.

[32]  G. Schiavo,et al.  Neurotoxins affecting neuroexocytosis. , 2000, Physiological reviews.

[33]  M. Naumann,et al.  Historical aspects of botulinum toxin , 1999, Neurology.

[34]  R. Stevens,et al.  Sequence homology and structural analysis of the clostridial neurotoxins. , 1999, Journal of molecular biology.

[35]  P. Dunnigan,et al.  Development of an In Vitro Bioassay for Clostridium botulinum Type B Neurotoxin in Foods That Is More Sensitive than the Mouse Bioassay , 1999, Applied and Environmental Microbiology.

[36]  P. Marini,et al.  SiMa, a new neuroblastoma cell line combining poor prognostic cytogenetic markers with high adrenergic differentiation. , 1999, Cancer genetics and cytogenetics.

[37]  R. Stevens,et al.  Crystal structure of botulinum neurotoxin type A and implications for toxicity , 1998, Nature Structural Biology.

[38]  G. Schiavo,et al.  The mechanism of action of tetanus and botulinum neurotoxins. , 1995, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.